Filing Details

Accession Number:
0001213900-24-008560
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-31 18:29:27
Reporting Period:
2024-01-29
Accepted Time:
2024-01-31 18:29:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1553643 Relmada Therapeutics Inc. RLMD Pharmaceutical Preparations (2834) 455401931
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1565832 Sergio Traversa C/O Relmada Therapeutics, Inc.
2222 Ponce De Leon Blvd, 3Rd Floor
Coral Gables, FL 33134
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-29 31,541 $3.71 175,565 No 4 P Direct
Common Stock Acquisiton 2024-01-30 40,999 $3.90 216,564 No 4 P Direct
Common Stock Acquisiton 2024-01-31 27,460 $4.00 244,024 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
  2. Purchase prices range from $3.69 to $3.75 per share, inclusive.
  3. Purchase prices range from $3.88 to $3.97 per share, inclusive.
  4. Purchase prices range from $3.95 to $4.05 per share, inclusive.